Instruments for detecting low-molecular weight substance

ABSTRACT

To provide the following instruments 1 and 2 as a low-molecular-weight substance detection instrument employing immunochromatography capable of detecting conveniently and sensitively detecting a low-molecular weight substance such as an environmental pollutant (e.g., a dioxin), as a target substance contained in a test sample: 1. an instrument, which comprises 1) a test sample application section with which a test sample is brought into contact; 2) a label product reaction section containing a label product containing, as a portion thereof, an antibody capable of binding to a target substance contained in the test sample, the label product being not bound to the reaction section; 3) an unbound label product capturing section containing an element capable of capturing the label product which is not bound to the target substance, the element being bound to the capturing section; and 4) a detection section containing a detection element which, when coming into contact with the target substance bound to the label product, causes a visually observable change, and 2. an instrument wherein a test sample is reacted with a labeled antibody containing, as a portion thereof, an antibody capable of binding to a target substance contained in the test sample, and the resultant reaction product is employed for detecting the target substance contained in the test sample.

TECHNICAL FIELD

The present invention relates to an instrument for detecting a specificsubstance.

BACKGROUND ART

In recent years, environmental pollutants such as dioxins and PCBs haveinvited serious problems in terms of environmental pollution, raisingconcerns about their adverse effects on living organisms, includinghumans. Conventionally, environmental pollutants such as dioxins havegenerally been detected by means of gas chromatography-mass spectrometry(GC-MS). GC-MS, which is employed as an official analytical method,provides excellent sensitivity and accuracy. However, GC-MS requires-aspecial apparatus, and therefore-involves problems; for example, highanalysis cost and requirement for an intricate analysis procedure.

In an attempt to solve the aforementioned problems associated withGC-MS, generally, environmental pollutants such as dioxins have beendetected by means of ELISA employing antibodies to-these chemicalsubstances, which is a more convenient method than GC-MS.

Although ELISA provides excellent quantification and exhibits highsensitivity, it involves, for example, the following problems: a specialapparatus is generally required for detection of a sample, and, whensuch an apparatus-is not employed, sample detection requires a longperiod of time (i.e., one hour or more). In view of the foregoing,immunochromatography has become of interest, by virtue of its simpleoperation, high sensitivity, and short detection time.

Among a variety of modes of ELISA, which has been most widely employedin immunochromatography, the sandwich method is frequently performed.The sandwich method employs two different antibodies capable of bindingto different sites of a high-molecular-weight analyte substance(substance which per se has antigenicity) (see, for example, JapanesePatent Application Laid-Open (kokai) Nos. 10-62420 and 2001-124771). Ina detection instrument employing the sandwich method, -development coloroccurs to a degree in proportion to the -concentration of thehigh-molecular-weight substance (target substance), whereby the targetsubstance is readily detected. Therefore, such a detection instrument iswidely employed in, for example, clinical laboratory tests performed inhospitals, and pregnancy tests performed at home.

When the target substance is a low-molecular-weight compound such as adioxin or PCB, the sandwich method is difficult to apply to the target-substance, since the low-molecular-weight compound and the antibodiesdiffer greatly in molecular weight. Therefore, when such alow-molecular-weight compound is detected by means ofimmunochromatography, conceivably, it is desirable to employ thecompetitive method, in which the low-molecular-weight compound (targetsubstance), and a low-molecular-weight compound or a compound similar tothe target low-molecular-weight compound are competitively bound to anantibody, followed by detection of the target low-molecular-weightcompound.

However, when the competitive method is employed, since the degree ofcoloring that is inversely proportional to the concentration of thetarget low-molecular-weight compound is necessarily used as an index,detection of the target substance becomes burdensome, as compared withthe case of the sandwich method, in which the degree of coloring that isproportional to the concentration of the target substance is used as anindex. Therefore, immunochromatography employing the competitive methodhas not yet prevailed, and involves difficulty in detectinglow-molecular-weight environmental pollutants such as dioxins and PCBs.

DISCLOSURE OF THE INVENTION

The present inventors have found that the aforementioned problems can besolved by providing an instrument for detecting a low-molecular-weightsubstance (hereinafter may be referred to as a “low-molecular-weightsubstance detection instrument”), the instrument employingimmunochromatography, which instrument comprises a test sampleapplication section with which a test sample is brought into contact,wherein a target substance contained in the test sample brought intocontact with the test sample application section is detected by use, asan index, of a labeling substance which forms a label productcontaining, as a portion thereof, an antibody capable of binding to thetarget substance contained in the test sample (hereinafter theinstrument may be referred to as “the present detection instrument”).

The target substance contained in the test sample, which is to bedetected by the present detection instrument, is an artificiallow-molecular-weight chemical substance which is present in a traceamount in the living environment (hereinafter such a substance may becollectively called an “environmental pollutant”). Particularlyappropriate examples of the environmental pollutant include substancessuspected of having endocrine disrupting effect, which are so-called“endocrine-disrupting chemicals.” Specific examples include dioxins,polychlorinated biphenyls (PCBs), polybrominated biphenyls (PBBs),hexachlorobenzene (HCB), pentachlorophenol (PCP),2,4,5-trichlorophenoxyacetic acid, 2,4-dichlorophenoxyacetic acid,amitrole, atrazine, alachlor, CAT (simazine), hexachlorocyclohexane,ethyl parathion, NAC (carbaryl), chlordane, oxychlordane,trans-nonachlor, 1,2-dibromo-3-chloropropane, DDT(dichlorodiphenyltrichloroethane), DDE(dichlorodiphenyltrichloroethylene), DDD(dichlorodiphenyldichloroethane), kelthane, aldrin, endrin, dieldrin,endosulfan (benzoepin), heptachlor, heptachlor epoxide, malathion,methomyl, methoxychlor, mirex, nitrofen, toxaphene, tributyltin,triphenyltin, trifluralin, alkylphenol (C5-C9), nonylphenol,octylphenol, bisphenol A, di-2-ethylhexyl phthalate, butylbenzylphthalate, di-n-butyl phthalate, dicyclohexyl phthalate, diethylphthalate, benzo(a)pyrene, 2,4-dichlorophenol, di-2-ethylhexyl adipate,benzophenone, 4-nitrotoluene, aldicarb, benomyl, kepone (chlordecone),manzeb (mancozeb), maneb, metiram, metribuzin, cypermethrin,esfenvalerate, fenvalerate, permethrin, vinclozolin, zineb, ziram,dipentyl phthalate, dihexyl phthalate, and dipropyl phthalate.

Among the above-described environmental pollutants, most typicalexamples are dioxins and PCBs. Examples of the dioxins include-29dioxins specified by Law Concerning Special Measures against Dioxins;i.e., dibenzodioxins such as 2,3,7,8-T₄CDD, 1,2,3,7,8-P₅CDD,1,2,3,4,7,8-H₆CDD, 1,2,3,6,7,8-H₆CDD, 1,2,3,7,8,9-H₆CDD,1,2,3,4,6,7,8-H₇CDD, and 1,2,3,4,6,7,8,9-O₈CDD; coplanar PCBs such as3,4,4′,5-T₄CB, 3,3′,4,4′-T₄CB, 3,3′,4,4′,5-P₅CB, 3,3′,4,4′,5,5′-H₆CB,2,3,3′,4,4′-PSCB, 2,3,4,4′,5-P ₅CB, 2,3′,4,4′,5-P₅CB, 2′,3,4,4′,5-P₅CB,2,3,3′,4,4′,5-H₆CB, 2,3,3′,4,4′,5′-H₆CB, 2,3′,4,4′,5,5′-H₆CB, and2,3,3′,4,4′,5,5′-H₇CB; and dibenzofurans such as 2,3,7,8-T₄CDF,1,2,3,7,8-P₅CDF, 2,3,4,7,8-P₅CDF, 1,2,3,4,7,8-H₆CDF, 1,2,3,6,7,8-H₆CDF,1,2,3,7,8,9-H₆CDF, 2,3,4,6,7,8-H₆CDF, 1,2,3,4,6,7,8-H₇CDF,1,2,3,4,7,8,9-H₇CDF, and 1,2,3,4,6,7,8,9-O₈CDF.

Examples of the PCBs include 2-monochlorobiphenyl,-3-monochlorobiphenyl,and 4-monochlorobiphenyl;

2,2′-dichlorobiphenyl, 2,3-dichlorobiphenyl, 2,3′-dichlorobiphenyl,2,4-dichlorobiphenyl, 2,4′-dichlorobiphenyl, 2,5-dichlorobiphenyl,2,6-dichlorobiphenyl, 3,3′-dichlorobiphenyl, 3,4-dichlorobiphenyl,3,4′-dichlorobiphenyl, 3,5-dichlorobiphenyl, and 4,4′-dichlorobiphenyl;

2,2′,3-trichlorobiphenyl, 2,2′,4-trichlorobiphenyl,2,2′,5-trichlorobiphenyl, 2,2′,6-trichlorobiphenyl,2,3,3′-trichlorobiphenyl, 2,3,4-trichlorobiphenyl,2,3,4′-trichlorobiphenyl, 2,3,5-trichlorobiphenyl,2,3,6-trichlorobiphenyl, 2,3′,4-trichlorobiphenyl,2,3′,5-trichlorobiphenyl, 2,3′,6-trichlorobiphenyl,2,4,4′-trichlorobiphenyl, 2,4,5-trichiorobiphenyl,2,4,6-trichlorobiphenyl, 2,4′,5-trichlorobiphenyl.2,4′,6-trichlorobiphenyl, 2′,3,4-trichlorobiphenyl,2′,3,5-trichlorobiphenyl, 3,3′,4-trichlorobiphenyl,3,3,5-trichlorobiphenyl, 3,4,4′-trichlorobiphenyl,3,4,5-trichlorobiphenyl, and 3,4′,5-trichlorobiphenyl;

2,2′,3,3′-tetrachlorobiphenyl, 2,2′,3,4-trichlorobiphenyl,2,2′,3,4′-tetrachlorobiphenyl, 2,2′,3,5-trichlorobiphenyl,2,2′,3,5′-tetrachlorobiphenyl, 2,2′,3,6-trichlorobiphenyl,2,2′,3,6′-tetrachlorobiphenyl, 2,2′,4,4′-tetrachlorobiphenyl,2,2′,4,5-tetrachlorobiphenyl, 2,2′,4,5′-tetrachlorobiphenyl,2,2′,4,6-tetrachlorobiphenyl, 2,2′,4,6′-tetrachlorobiphenyl.,2,2′,5,5′-tetrachlorobiphenyl, 2.,2′,5,6′-tetrachlorobiphenyl,2,2′,6,6′-.tetrachlorobiphenyl, 2,3,3′,4-tetrachlorobiphenyl,2,3,3′,4′-tetrachlorobiphenyl, 2,3,3′,5-tetrachlorobiphenyl,2,3,3′,5′-tetrachlorobiphenyl, 2,3,3′,6-tetrachl-orobiphenyl,2,3,4,4′-tetrachlorobiphenyl, 2,3,4,5-tetrachlorobiphenyl,2,3,4,6-tetrachlorobiphenyl, 2,3,4′,5-tetrachlorobiphenyl,2,3,4′,6-tetrachlorobiphenyl, 2,3,5,6-tetrachlorobiphenyl,2,3′,4,4′-tetrachlorobiphenyl, 2,3′,4,5-tetrachlorobiphenyl,2,3′,4,5′-tetrachlorobiphenyl, 2,3′,4,6-tetrachlorobiphenyl,2,3′,4′,5-tetrachlorobiphenyl, 2,3′,4′,6-tetrachlorobiphenyl,2,3′,5,5′-tetrachlorobiphenyl, 2,3′,5′,6-tetrachlorobiphenyl,2,4,4′,5-tetrachlorobiphenyl, 2,4,4′,6-tetrachlorobiphenyl,2′,3,4,5-tetrachlorobiphenyl, 3,3′,4,4′-tetrachlorobiphenyl,3,3′,4,5-tetrachlorobiphenyl, 3,3′,4,5′-tetrachlorobiphenyl,3,3′,5,5′-tetrachlorobiphenyl, and 3,4,4′,5-tetrachlorobiphenyl;

2,2′,3,3′,4-pentachlorobiphenyl, 2,2′,3,3′,5-pentachlorobiphenyl,2,2′,3,3′,6-pentachlorobiphenyl, 2,2′,3,4,4′-pentachlorobiphenyl,2,2′,3,4,5-pentachlorobiphenyl, 2,2′,3,4,5′-pentachlorobiphenyl,2,2′,3,4,6-pentachlorobiphenyl, 2,2′,3,4,6′-pentachlorobiphenyl,2,2′,3,4′,5 -pentachlorobiphenyl, 2,2′,3,4′,6-pentachlorobiphenyl,2,2′,3,5,5′-pentachlorobiphenyl, 2,2′,3,5,6′-pentachlorobiphenyl,2,2′,3,5,6′-pentachlorobiphenyl, 2,2′,3,5′,6-pentachlorobiphenyl,2,2′,3,6,6′-pentachlorobiphenyl, pentachlorobiphenyl,2,2′,3′,4,5-pentachlorobiphenyl, 2,2′,3′,4,6-pentachlorobiphenyl,2,2′,4,4′,5-pentachlorobiphenyl, 2,2′,4,4′,6-pentachlorobiphenyl,2,2′,4,5,5′-pentachlorobiphenyl, 2,2′,4,5,6′-pentachlorobiphenyl,2,2′,4,5′,6-pentachlorobiphenyl, 2,2′,4,6,6′-pentachlorobiphenyl,2,3,3′,4,4′-pentachlorobiphenyl, 2,3,3′,4,5-pentachlorobiphenyl,2,3,3′,4′,5-pentachlorobiphenyl, pentachlorobiphenyl,2,3,3′,4,5′-pentachlorobiphenyl, 2,3,3′,4,6-pentachlorobiphenyl,2,3,3′,4′,6-pentachlorobiphenyl, 2,3,3′,5,5′-pentachlorobiphenyl,2,3,3′,5,6-pentachlorobiphenyl, 2,3,3′,5′,6-pentachlorobiphenyl,2,3,4,4′,5-pentachlorobiphenyl, 2,3,4,4′,6-pentachlorobiphenyl,2,3,4,5,6-pentachlorobiphenyl, 2,3,4′,5,6-pentachlorobiphenyl,2,3′,4,4′,5-pentachlorobiphenyl, 2,3′,4,4′,6-pentachlorobiphenyl,2,3′,4,5,5′-pentachlorobiphenyl, 2,3′,4,5′,6-pentachlorobiphenyl, 2′,3,3′,4,5-pentachlorobiphenyl, 2′,3,4,4′,5-pentachlorobiphenyl,2′,3,4,5,5′-pentachlorobiphenyl, 2′,3,4,5,6′-pentachlorobiphenyl,3,3′,4,4′,5-pentachlorobiphenyl, and 3,3′,4,5,5′-pentachlorobiphenyl;

2,2′,3,3′,4,4′-hexachlorobiphenyl, 2,2′,3,3′,4,5-hexachlorobiphenyl,2,2′,3,3′,4,5′-hexachlorobiphenyl,. 2,2′,3,3′,4,6-hexachlorobiphenyl,2,2′,3,3′,4,6′-hexachlorobiphenyl, 2,2′,3,3′,5,5′-hexachlorobiphenyl,2,2′,3,3′,5,6-hexachlorobiphenyl, 2,2′,3,3′,5,6′-hexachliorobiphenyl,2,2′,3,3′,6,6′-hexachlorobiphenyl, 2-2′,3,4′,4,5-hexachlorobiphenyl,2,2′,3,4,4′,5′-hexachlorobiphenyl, 2,2′,3,4,4′,6-hexachlorobiphenyl,2,2′,3,4,4′,6′-hexachlorobiphenyl, 2,2′,3,4,4,5′-hexachlorobiphenyl,2,2′,1,3,4,5,6-hexachlorobiphenyl, 2,2′,3,4,5,6′-hexachlorobiphenyl,2,2′,3,4,51,6-hexachlorobiphenyl, 2,21,3,4,6,6′-hexachlorobiphenyl,2,2′,3,4′,5,5′-hexachlorobiphenyl, 2,2′,3,4′,5,6-hexachlorobiphenyl,2,2′,3,4′,5,6′-hexachlorobiphenyl, 2,2′,3,4′,5′,6-hexachlorobiphenyl,2,2′,3,4′,6,6′-hexachlorobiphenyl, 2,2′,3,5,5′,6-hexachlorobiphenyl,2,2′,3,5,6,6′-hexachlorobiphenyl, 2,2′,4,4′,5,5′-hexachlorobiphenyl,2,2′,4,4′,5,6′-hexachlorobiphenyl, 2,2′,4,4′,6,6′-hexachlorobiphenyl,2,3,3′,4,4′,5-hexachlorobiphenyl, 2,3,3′,4,4′,5′-hexachlorobiphenyl,2,3,3′,4,4′,6-hexachlorobiphenyl, 2,3,3′,4,5,5′-hexachlorobiphenyl,2,3,3′,4,5,6-hexachlorobiphenyl, 2,3,3′,4,5′,6-hexachlorobiphenyl,2,3,3′,4′,5,5′-hexachlorobiphenyl, 2,3,3′,4′,5,6-hexachlorobiphenyl,2,3,3′,4′,5′,6-hexachlorobiphenyl, 2,3,3′,5,5′,6-hexachlorobiphenyl,2,3,4,4′,5,6-hexachlorobiphenyl, 2,3′,4,4′,5,5′-hexachlorobiphenyl,2,3′,4,4′,5′,6-hexachlorobiphenyl, and3,3′,4,4′,5,5′-hexachlorobiphenyl;

2,2′,3,3′,4,4′,5-heptachlorobiphenyl,2,2′,3,3′,4,4′,6-heptachlorobiphenyl,2,2′,3,3′,4,5,5′-heptachlorobiphenyl,2,2′,3,3′,4,5,6-heptachlorobiphenyl,2,2′,3,3′,4,5,6′-heptachlorobiphenyl,2,2′,3,3′,4,5′,6-heptachlorobiphenyl,2,2′,3,3′,4,6,6′-heptachlorobiphenyl,2,2′,3,3′,4′,5,6′-heptachlorobiphenyl,2,2′,3,3′,5,5′,6-heptachlorobiphenyl,2,2′,3,3′,5,5,6′-heptachlorobiphenyl,2,2′,3,4,4′,5,5′-heptachlorobiphenyl,2,21,3,4,4′,5,6-heptachlorobiphenyl,2,2′,3,4,4′,5,6′-heptachlorobiphenyl,2,2′,3,4,4′,5′,6-heptachlorobiphenyl,2,2′,3,4,4′,6,6′-heptachlorobiphenyl,2,2′,3,4,5,5′,6-heptachlorobiphenyl,2,2′,3,4,5,6,6′-heptachlorobiphenyl,2,2′,3,4′,5,5′,6-heptachlorobiphenyl,2,2′,3,4′,5,6,6′-heptachlorobiphenyl,2,2′,3′,4,4′,5,5′-heptachlorobiphenyl,2,21,3′,4,4′,5,6-heptachlorobiphenyl,2,21,3′,4,4′,51,6-heptachlorobiphenyl,2,2′,3′,4,5,5′,6-heptachlorobiphenyl, and2,2′,3′,4,5,5′6′-nonachlorobiphenyl; and heptachlorobiphenyl;

2,2′,3,3′,4,4′,5,5′-octachlorobiphenyl,2,2′,3,3′,4,4′,5,6-octachlorobiphenyl,2,-2′,3,3′,4,4′,5′,6-octachlorobiphenyl,2,2′,3,3′,4,4′,6,6′-octachlorobiphenyl,2,2′,3,3′,4,5,5′,6-octachlorobiphenyl,2,2′,3,3′,4,5,6,6′-octachlorobiphenyl,2,2′,3,3′,4,5′,6,6′-octachlorobiphenyl,2,2′,3,3′,4′,5,5′,6-octachlorobiphenyl,2,2′,3,3′,5,5′,6,6′-octachlorobiphenyl,2,2′,3,4,4′,5,5′,6-octachlorobiphenyl,2,2′,3,4,4′,5,6,6′-octachlorobiphenyl, and2,3,3′,4,4′,5,5′,6-octachlorobiphenyl;

2,2′,3,3′,4,4′,5,5′,6-nonachlorobiphenyl,2,2′,3,3′,4,4′,5,6,6′-nonachlorobiphenyl, and2,2′,3,3′,4,5,5′,6,6′-nonachlorobiphenyl; and decachlorobiphenyl.

When an antibody to dioxins or PCBS, which is to be employed in theaforementioned present detection instrument, is prepared, a dioxin orPCB isomer (i.e., the target substance of the antibody) suitable for thecase where toxicity of dioxins or PCBs contained in the test sample isestimated differs from that suitable for the case where the total amountof such environmental pollutants contained in the test sample isestimated. For example, in the case where the toxicity of dioxinscontained in the test sample is estimated, 1,2,3,7,8-P₅CDD,2,3,4,7,8-P₅CDF, 3,3′,4,4′,5-P₅CB, or the like, which greatly affectsthe total toxicity of dioxins contained in the test sample, is suitablefor use as the target substance. Meanwhile, in the case where the totalamount of dioxins contained in the test sample is estimated,1,2,3,4,6,7,8,9-O₈CDD, 1,2,3,4,6,7,8,9-O₈CDF, 2,3′,4,4′,5-P₅CB, or thelike, which is highly likely to be contained, as a dioxin, in a largeamount in the test sample, is suitable for use as the target substance.

No particular limitations are imposed on the test sample, so long as itcontains an environment-related low-molecular-weight substance such as adioxin or PCB. Examples of the test sample include air samples, soilsamples, and water samples such as. lake water samples and sea watersamples. Before being applied to the present detection instrument, thetest sample may be subjected to any suitable preliminary treatment, suchas dilution, filtration, or concentration, in accordance with itscharacteristics.

Two main modes of the present detection instrument are contemplated asdescribed below.

A first mode of the present detection instrument comprises 1) a testsample application section with which a test sample is brought intocontact; 2) a label product reaction section containing a label productcontaining, as a portion thereof, an antibody capable of binding to atarget substance contained in the test sample, the label product beingnot bound to the reaction section; 3) an unbound label product capturingsection containing an element capable of capturing the free labelproduct (i.e., the label product which is not bound to the targetsubstance), the element being bound to the capturing section; and 4) adetection section containing a detection element which, when coming intocontact with the target substance bound to the label product, causes avisually observable change (hereinafter the first mode may be referredto as “the present detection instrument A”).

In a second mode of the present detection instrument(low-molecular-weight substance detection instrument), a test sample isreacted with a labeled antibody containing, as a portion thereof, anantibody capable of binding to a target substance contained in the testsample, and the resultant reaction product is employed for detecting thetarget substance contained in the test sample (hereinafter the secondmode may be referred to as “the present detection instrument B”).

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a top plan view showing an embodiment-of the present detectioninstrument A.

FIG. 2 is a vertical cross-sectional view showing the embodiment of thepresent detection instrument A.

FIG. 3 is a top plan view showing an embodiment of the present detectioninstrument B.

FIG. 4 is a-vertical cross-sectional view showing the embodiment of thepresent detection instrument B.

FIG. 5 shows a labeled antibody sealed in a container, the antibodyserving as a constitutive element of the present detection set.

BEST MODE FOR CARRYING OUT THE INVENTION

The Present Detection Instrument A

FIG. 1 is a top plan view showing an embodiment of the present detectioninstrument A; and FIG. 2 is a vertical cross-sectional view showing thepresent detection instrument A 10 of FIG. 1, as taken: along solid lineI-I′.

The present detection instrument A 10 includes a test sample applicationsection 1, a label product reaction section 2, a membrane 6, anabsorption section 5, and a strip-shaped thin film 7, wherein a portionof each of the sections 1, 2, and 5 and the entirety of the membrane 6are bonded onto the upper surface of the thin film 7. The membrane 6includes an unbound label product capturing section 3 and a detectionsection 4. More specifically, a first end portion of the test sampleapplication section 1 is bonded to a first end portion of the thin film7. A second end portion of the test sample application section 1 is incontact with the label product reaction section 2 so as to cover theupper surface of a first end portion of the section 2, the first endportion of the section 2 being located adjacent to the portion where thesection 1 is bonded to the thin film 7 (i.e., the first end portion ofthe section 1) and being bonded to the thin film 7. A second end portionof the label product reaction section 2 is in contact with the membrane6 so as to cover the upper surface of a first end portion of themembrane 6, the first end portion of the membrane 6 being locatedadjacent to the portion where the section 2 is bonded to the thin film 7(i.e., the first end portion of the section 2), and the entire surfaceof the membrane 6 being bonded to the thin film 7. A first end portionof the absorption section 5 is bonded to a second end portion of thethin film 7. A second end portion of the absorption section 5 is incontact with the membrane 6 so as to cover the upper surface of a secondend portion of the membrane 6.

The unbound label product capturing section 3 and the detection section4 are provided on the membrane 6 by fixating chemical componentsconstituting these sections onto the membrane 6.

In the present detection instrument A 10, a test sample is brought intocontact with the test sample application section 1, and the test samplemigrates from the section 1 toward the absorption section 5 by means ofcapillary action, whereby a low-molecular-weight substance contained inthe test sample is detected (hereinafter, the side of the presentdetection instrument A on which the test sample application section isprovided may be referred to as “the upstream side,” and the side of theinstrument A on which the absorption section is provided may be referredto as “the downstream side”). In FIGS. 1 and 2, an arrow 8 shows thedirection of migration of the test sample from the upstream side to thedownstream side.

No particular limitations are imposed on the material of the test sampleapplication section 1, so long as the test sample brought into contactwith the section 1 can migrate to the label product reaction section 2,which is located downstream of the section 1, by means of capillaryaction. Examples of the material include papers such as filter paper;fabrics such as raised fabric; cotton; and glass fiber.

When the test sample comes into contact with the test sample applicationsection 1 of the present detection instrument A 10, and then reaches theportion of the section 1 that is in contact with the label productreaction section 2, the test sample migrates to the section 2 by meansof capillary action.

The label product reaction section 2 contains, in an unbound state, alabel product containing, as a portion thereof, an antibody capable ofbinding to a target substance contained in the test sample.

The antibody employed in the label product reaction section 2 can beproduced through a customary method by use of an environmental pollutantto be detected, serving as an immunogen (if desired, the immunogen maybe formed of a carrier protein and a hapten which targets theenvironmental pollutant to be detected).

In the case where the antibody employed in the section 2 is a polyclonalantibody, the antibody can be produced from immune serum derived from ananimal immunized with an environmental pollutant (e.g., a dioxin or aPCB) to be detected, serving as an immunogen. Meanwhile, in the casewhere the antibody employed in the section 2 is a monoclonal antibody,the antibody can be produced through the following procedure:.ahybridoma is prepared from myeloma cells of an animal and immunocytes ofan animal which is immunized in a manner similar to that of theaforementioned polyclonal antibody, and a clone which produces anantibody recognizing an environmental pollutant (e.g., a dioxin or aPCB) to be detected is selected by use of the hybridoma, followed byculturing of the clone.

No particular limitations are imposed on the animal to be immunized, andthe animal may be, for example, mouse or rat. In the case where themonoclonal antibody is produced, preferably, the animal is chosen inconsideration of compatibility with myeloma cells employed for cellfusion.

Immunization can be performed by means of a generally employed method;for example, a method in which the aforementioned immunogen isadministered to an animal to be immunized through, for example,intravenous, intradermal, subcutaneous, or intraperitoneal injection.

More specifically, the aforementioned immunogen high is, if desired,employed in combination with a typical adjuvant an be administeredseveral times to an animal to be immunized every two to four weeksthrough the aforementioned means, to thereby prepare immune serum forproducing the polyclonal antibody, or immunocytes (e.g., immunizedspleen cells) for producing the monoclonal antibody.

In the case where the monoclonal antibody is produced, the immunocytesmay be subjected to cell fusion with known -myeloma cells serving asparental cells. Examples of the known myeloma cells include SP2/0-Ag14,P3-NS1-1-Ag4-1, MPC11-45, and 6.TG1.7 (which are derived from mouse);210.RCY.Ag1.2.3 (which is derived from rat); and SKO-007 andGM15006TG-A12 (which are derived from human).

Cell fusion between the aforementioned immunocytes and myeloma cells canbe carried out by means of a generally known method, such as the methodof Kohler and Milstein (Köhler, G. and Milstein, C., Nature, 256, 495(1975)).

More specifically, the cell fusion is carried out in a generallyemployed culture medium to which, if desired, an adjuvant (e.g.,dimethyl sulfoxide) is added for enhancing fusion efficiency, in thepresence of a generally known fusion promoter such as polyethyleneglycol (PEG) or Sendai virus (HVJ), to thereby prepare a hybridoma.

Separation of a target hybridoma can be performed through culturing in agenerally employed screening medium such as HAT (hypoxanthine,aminopterin, and thymidine) medium. Specifically, a-target hybridoma canbe separated by performing culturing in the screening medium for asufficient time for apoptosis of cells other than the hybridoma. Througha typical limiting dilution technique, the thus-prepared hybridoma canbe employed for screening and monocloning of a target monoclonalantibody.

A cell strain which produces the target monoclonal antibody can bescreened by means of a generally employed screening method, such asELISA, the plaque method, spotting, agglutination reaction, theouchterlony method, or RIA.

The thus-prepared hybridbma which produces the monoclonal antibodyrecognizing an environmental pollutant can be subcultured in a typicalmedium and stored in liquid nitrogen for a long period of time.

The target monoclonal antibody can be collected from the hybridoma bymeans of, for example, a method in which the hybridoma is cultured in aconventional technique, and the monoclonal antibody is obtained from theresultant supernatant; or a method in which the hybridoma isadministered to an animal exhibiting compatibility with the hybridoma tothereby proliferate the hybridoma, and the monoclonal antibody isobtained from ascites of the animal.

The above-obtained polyclonal or monoclonal antibody may be purifiedthrough generally employed means, such as salting out,-gel filtration,or affinity chromatography.

In general, the label product employed in the label product reactionsection 2 is preferably a labeled antibody prepared by labeling theaforementioned antibody to an environmental pollutant with a labelingsubstance.

Examples of the labeling substance which may be employed includemetallic colloidal particles such as gold colloidal particles; latexparticles; and enzymes exhibiting color-developing ability, such ashorseradish peroxidase. Such a labeling substance and the antibody arebound together by means of a customary method, and the thus-boundproduct is employed in the label product reaction section 2.

The aforementioned label product must be present, in an unbound state,in the material constituting the label product reaction section 2, suchthat, regardless of whether or not a target substance is present in thetest sample, the label product can migrate, together with the testsample which has migrated from the test sample application section 1,toward the unbound label product capturing section 3, which is locateddownstream of the section 2, by means of capillary action. Therefore,preferably, the aforementioned label product is simply held in the labelproduct reaction section through, for example, permeation of the labelproduct into the material of the reaction section. The material of thelabel product reaction 'section 2 is preferably a material whichfacilitates such simple holding or elution of the label product.Specific examples of such a preferred material include papers such asfilter paper; fabrics such as raised fabric; cotton; and glass fiber.

When a target substance is present in the test sample, a labeled complexformed through binding between the target substance and the labelproduct, as well as the free label product (i.e., the label product notbound to the target substance) migrate toward the downstream side,whereas when a target substance is not present in the test sample,merely the free label product migrates toward the downstream side.

In the present detection instrument A 10, the unbound label productcapturing section 3 and the detection section 4 are provided on themembrane, the section 4 being located downstream of the section 3. Themembrane is preferably formed of a material which enables a liquid phaseto migrate therethrough by means of capillary action, such as a porouschromatomembrane or a nitrocellulose membrane. Particularly, a porouschromatomembrane is preferred, since a labeling substance, such as aprotein (e.g., horseradish peroxidase), metallic colloidal particles(e.g., gold colloidal particles), or latex particles, can readilymigrate through the membrane.

The labeled complex and/or the free label product, which has migratedfrom the upstream side by means of capillary action, comes into contactwith the unbound label product capturing section 3. The unbound labelproduct capturing section has an element capable of capturing merely thefree label product (i.e., the label product not bound to the targetsubstance). Examples of the element include a substance which can reactwith and bind to the antibody to the target substance, the antibodyconstituting the label product. Specific examples include the targetsubstance per se, and substances which are similar to the targetsubstance and can react with and bind to the antibody. The targetsubstance or the like must be bound to the unbound label productcapturing section 3, such that the target substance or the like does notmigrate as a liquid phase migrates through the section 3. Since thetarget substance or the like has low molecular weight, preferably, thetarget substance or the like is bound to a carrier protein such as BSA,and the target substance or the like bound to the protein is bound andfixated to the unbound label product capturing section 3 by means of acustomary protein fixation method.

As described above, the unbound label product capturing section 3 has anelement capable of capturing merely the free label product (i.e., thelabel product not bound to the target substance). Therefore, in the casewhere the test sample contains a target substance, when the labeledcomplex and the free label product migrate from the upstream side to theunbound label product capturing section 3, merely the free label productis captured by the section 3, and merely the-labeled complex migratestoward the downstream side. Meanwhile, in the case where the test samplecontains no target substance, merely the free label product migrates tothe unbound label product capturing section 3, the free label product iscompletely captured by the section 3, and merely a liquid phasecontaining no label product migrates to the downstream side.

Subsequently, the liquid phase which has passed through the unboundlabel product capturing section 3 comes into contact with the detectionsection 4, which is provided downstream of the section 3. The detectionsection 4 has a labeling substance visualization element capable ofvisualizing the labeling substance employed in the label product. Thelabeling substance visualization element corresponds to the employedlabeling substance. When, for example, the label product employs anoriginally visually observable labeling substance (e.g., gold colloidalparticles), the visualization element is preferably a detection elementcapable of capturing the labeled complex in a concentrated form; forexample, an antibody specific to the antibody specific to the employedenvironmental pollutant (i.e., an anti-immunoglobulin antibody). Theanti-immunoglobulin antibody is preferably an antibody which binds to aportion (other than the paratope) of the antibody specific to theemployed environmental pollutant, such as an anti-Fc antibody.

When such an anti-immunoglobulin antibody is densely fixated, as adetection element, to the detection section 4, the labeling substancewhich has migrated together with a liquid phase can be concentrated andvisualized by the section 4.

Meanwhile, in the case where the employed labeling substance is anenzyme having a color-developing ability, such as horseradishperoxidase; i.e., in the case where a substrate must be brought intocontact with the enzyme at the detection section 4 for colordevelopment, preferably, the detection element of the detection section4 is prepared by binding-an anti-immunoglobulin antibody to, forexample, a reagent capable of visualizing the employed labelingsubstance, rather than an anti-immunoglobulin antibody being employedsolely as the detection element.

In any of the aforementioned cases, in order to visualize the labelingsubstance, the detection element such as an anti-immunoglobulin antibodyis preferably bound to the detection section 4, such that the detectionelement does not migrate from the section 4 together with a liquid phaseby means of capillary action. No particular limitations are imposed onthe binding state of the detection element, so long as the detectionelement does not migrate from the detection section 4 together with aliquid phase. For example, in the case where the detection element is anantibody which binds to a portion (other than the-paratope) of theantibody specific to an environmental pollutant to be detected, when asolution of the detection element (antibody) is added dropwise to thecorresponding portion of the detection section 4, a desired bindingstate of the detection element is established.

Finally, the absorption section 5 absorbs a liquid phase which hasmigrated from the upstream side toward the downstream side by means ofcapillary action. In the present detection instrument A, the absorptionsection 5 is an optional element. However, the absorption section 5 ispreferably provided on the detection instrument for facilitatingmigration of the test sample through the membrane.

As described above, in the case where the test sample contains a targetsubstance, in the present detection instrument A 10, the targetsubstance (i.e., low-molecular-weight compound) binds, at the labelproduct reaction section 2, to a label product which reacts specificallywith the target substance, to thereby form a labeled complex.Subsequently, the thus-formed labeled complex migrates through themembrane 6. The labeled complex is not captured by the unbound labelproduct capturing section 3, but the complex reaches the detectionsection 4. Since a substance capable of visualizing the labeled complexis fixated onto the detection section 4, the complex is concentrated atthe section 4, whereby a visually observable band of the complex isdetected.

Meanwhile, in the case where the test sample contains no targetsubstance, a labeled complex as described above is not formed at thelabel product reaction section 2, and the free label product migratesthrough the membrane together with a liquid phase. The free labelproduct is completely captured by the unbound label product capturingsection 3, and thus no label product reaches the detection section 4. Asa result, a band of the label product is not detected at the detectionsection 4.

As described above, the present invention provides means for detecting,by use of a positive index, an environmental pollutant, which hasconventionally been. difficult to detect.

The Present Detection Instrument B

Although the present detection instrument A described above isconsidered to be very beneficial to the industry, the instrument A tendsnot to exhibit high detection sensitivity as expected.

Specifically, the present detection instrument A tends to raise, forexample, the following problems.

1) When a test sample is brought into contact with the test sampleapplication section, a solvent contained in the test sample and thelabel product of the label product reaction section rapidly reach theunbound label product capturing section provided on the membrane.Therefore, when the label product reaction section contains a largeamount of the label product, the capturing section encountersdifficulty-in completely capturing the unbound label product. As aresult, false-positive reaction may occur at the detection section, evenwhen the test sample contains no target substance.

2) When treatment with a surfactant is carried out for promotingmigration of the label product from the label product reaction sectionto the membrane, antigen-antibody reaction which is supposed to occur isinhibited. Therefore, even when the test sample contains no targetsubstance, the capturing section may fail to completely capture theunbound label product, leading to occurrence of false-positive reactionat the detection section.

3) When the test sample is brought into contact with the test sampleapplication section, a solvent contained in the test sample and thelabel product of the label product reaction section rapidly migratethrough the membrane, and thus only a portion of the-target substancecontained in the test sample reacts with the label product. Therefore,even when the amount of the test-sample is increased, difficulty wouldbe encountered in enhancing detection sensitivity.

While avoiding the problems associated with the present detectioninstrument A, the present detection instrument B can detect the targetsubstance contained in the test sample; i.e., a low-molecular-weightsubstance such as an environmental pollutant (e.g., a dioxin).

FIG. 3 is a top plan view showing an embodiment of the present detectioninstrument B; and FIG. 4 is a vertical cross-sectional view showing thepresent detection instrument B 30 of FIG. 3, as taken along solid lineII-II′.

The present detection instrument B 30 includes a reaction productcontact section 21, a membrane 25, an absorption section 24, and astrip-shaped thin film 26, wherein portions of the respective sections21 and 24 and the entirety of the membrane 25 are bonded onto the uppersurface of the thin film. The membrane 25 includes an unbound labeledantibody capturing section 22 and a detection section 23.

More specifically, a first end portion of the reaction product contactsection 21 is bonded to a first end portion of the thin film 26. Asecond end portion of the reaction product contact section 21 is incontact with the membrane 25 so as to cover the upper surface of a firstend portion of the membrane 25, the first end portion of the membrane 25being located adjacent to the portion where the section 21 is bonded tothe thin film 26 (i.e., the first end portion of the section 21) and theentire surface of the membrane 25 being bonded to the thin film 26. Afirst end portion of the absorption section 24 is bonded to a second endportion of the thin film 26. A second end portion of the absorptionsection 24 is in contact with the membrane 25 so as to cover the uppersurface of a second end portion of the membrane 25.

The unbound labeled antibody capturing section 22 and the detectionsection 23 are provided on the membrane 25 by fixating chemicalcomponents constituting these sections onto the membrane 25.

The present detection instrument B 30 employs immunochromatography, inwhich a reaction product which has previously formed through contactbetween a test sample and a labeled antibody is brought into contactwith the reaction product contact section 21, rather than the testsample per se being brought into contact with, for example, a testsample application section. Therefore, the present detection instrumentB 30 differs from a conventional detection instrument employingimmunochromatography in which a test sample per se is brought intocontact with a test sample application section.

In the case of the present detection instrument B 30, the test samplecan be sufficiently reacted with the labeled antibody. Therefore, when areaction product formed through this reaction is applied to the presentdetection instrument B 30, the labeled antibody can be prevented fromrapidly reaching the unbound labeled antibody capturing section, wherebythe aforementioned false-positive reaction is suppressed, and detectionsensitivity is enhanced. Thus, the detection instrument can convenientlyand sensitively detect, for example, a low-molecular-weight substancepresent in the environment which, even in a trace amount, would causeproblems.

In the present detection instrument B 30, the above-formed reactionproduct is brought into contact with the reaction product contactsection 21, and the reaction product migrates from the section 21 towardthe absorption section 24 by means of capillary action, whereby alow-molecular-weight substance contained in the test sample is detected(hereinafter, the side of the present detection instrument B on whichthe reaction product contact section is provided may be referred to as“the upstream side,” and the side of the instrument B on which theabsorption section is provided may be referred to as “the downstreamside”). In FIGS. 3 and 4, an arrow 29 shows the direction of migrationof the reaction product from the upstream side to the downstream side.

Since the labeled antibody is reacted with the test sample before thereaction product is applied to the present detection instrument B, thelabeled antibody is not an essential element of the present detectioninstrument B. However, the labeled antibody is essential for detecting alow-molecular-weight substance by use of the present detectioninstrument B.

The present invention provides a method of using the present detectioninstrument B, which comprises bringing, into contact with the reactionproduct contact section, a reaction product formed from a test sampleand a labeled antibody capable of binding to a target substancecontained in the test sample; and detecting-a complex of the labeledantibody and the target substance, and/or the free labeled antibody(i.e., the labeled antibody which is not bound to the target substance),the complex and the free labeled antibody being contained in thereaction product, to thereby detect the target substance contained inthe test sample (hereinafter the method may be-referred to as “thepresent use method”).

The present invention also provides a set for detecting alow-molecular-weight substance, comprising the present detectioninstrument B and a labeled antibody as constitutive elements forperforming the present use method (hereinafter the set may be referredto as “the present detection set”).

The antibody which can be employed as a portion of the labeled antibodyemployed as an element of the present detection set; i.e., an antibodycapable of binding to a target substance contained in the test sample,may be a polyclonal antibody or a monoclonal antibody. Such an antibodycan be produced through a customary method by use, as an immunogen, of alow-molecular-weight substance to be detected (e.g., an environmentalpollutant) (if desired, the immunogen may be formed by binding a carrierprotein to a hapten which targets an environmental pollutant to bedetected). This customary production method is similar to that describedabove in the case of the present detection instrument A.

In the case where the present detection instrument B is employed, thelabeled antibody is preferably maintained in a dry condition. Forexample, a labeled antibody 291 is dried by means of, for example,thermal drying, vacuum drying, or freeze-drying, in the presence of astabilizer such as a sugar, a surfactant, or a polyhydric alcohol (e.g.,glycerol), and the thus dried labeled antibody 291 is stored in, forexample, a sealable container 292 while maintaining the antibody in adry condition (preferably using a desiccant) (FIG. 5: A typicalembodiment of the present detection set includes the present detectioninstrument B 30, and the labeled antibody 291 sealed in the container292.).

In the case where a test sample is subjected to detection by means ofthe present use method by use of the present detection instrument B 30or the present detection set including the instrument as a constitutiveelement, when a target substance is present in the test sample, alabeled complex formed through binding between the target substance andthe labeled antibody, and the free labeled antibody (i.e., the labeledantibody not bound to the target substance), which are contained in thereaction product, migrate toward the downstream side. Meanwhile, when atarget substance is not present in the test sample, since a labeledcomplex is not contained in the reaction product, merely the freelabeled antibody migrates toward the downstream side.

As described above, in the present detection instrument B 30, theunbound labeled antibody capturing section 22 and the detection section23 are provided on the membrane 25, the section 23 being locateddownstream of the section 22. The membrane is preferably formed of amaterial which enables a liquid phase to migrate therethrough by meansof capillary action, such as a porous chromatomembrane or anitrocellulose membrane. Particularly, a porous chromatomembrane ispreferred, since a labeling substance, such as a protein (e.g.,horseradish peroxidase), metallic colloidal particles (e.g., goldcolloidal particles), or latex particles, can readily migrate throughthe membrane.

Firstly, the labeled complex and/or the free labeled antibody, which hasmigrated from the upstream side by means of capillary action, comes intocontact with the unbound labeled antibody capturing section 22. Theunbound labeled antibody capturing section has an element capable ofcapturing merely the free labeled antibody (i.e., the labeled antibodynot bound to the target substance). Examples of the element include asubstance which can react with and bind to the antibody to the targetsubstance, the antibody constituting the labeled antibody.. Specificexamples include the target substance per se, and substances which aresimilar to the target substance and can react with and bind to theantibody. The target substance or the like must be bound to the unboundlabeled antibody capturing section 22, such that the target substance orthe like does not migrate as a liquid phase migrates through the section22. Since the target substance or the like has low molecular weight,preferably the target substance or the like is bound to a carrierprotein such as BSA, and the target substance or the like bound to theprotein is bound and fixated to the unbound labeled antibody capturingsection 22 by means of a customary protein fixation method.

As described above, the unbound labeled antibody capturing section 22has an element capable of capturing merely the free labeled antibody(i.e., the labeled antibody not bound to the target substance).Therefore, in the case where the test sample contains a targetsubstance, when the labeled complex and the free labeled antibodymigrate from the upstream side to the unbound labeled antibody capturingsection 22, merely the free labeled antibody is captured by the section22, and merely the labeled complex migrates toward the downstream side.Meanwhile, in the case where the test sample contains no targetsubstance, merely the free labeled antibody migrates to the unboundlabeled antibody capturing section 22. Therefore, the free labeledantibody is almost completely captured by the section 22, and a liquidphase containing virtually no labeled antibody migrates to thedownstream side.

Subsequently, the liquid phase which has passed through the unboundlabeled antibody capturing section 22 comes into contact with thedetection section 23, which is provided downstream of the section 22.The detection section 23 has a labeling substance visualization elementfor visualizing the labeling substance employed in the labeled antibody.The labeling substance visualization element corresponds to the employedlabeling substance. When, for example, the labeled antibody employs anoriginally visually observable labeling substance (e.g., gold colloidalparticles), the visualization element is preferably a detection elementcapable of capturing the labeled complex in a concentrated form; forexample, an antibody specific to the antibody specific to the employedenvironmental pollutant (i.e., an anti-immunoglobulin antibody). Theanti-immunoglobulin antibody is preferably an antibody which binds to aportion (other than the paratope) of the antibody specific to theemployed environmental pollutant, such as an anti-Fc antibody.

When such an anti-immunoglobulin antibody is densely fixated, as adetection element, to the detection section 23, the labeling substancewhich has migrated together with a liquid phase can be concentrated andvisualized by the section 23.

Meanwhile, in the case where the employed labeling substance is anenzyme having a color-developing ability, such as horseradishperoxidase; i.e., in the case where a substrate must be brought intocontact with the enzyme at the detection section 23 for colordevelopment, preferably, the detection element of the detection section23 is prepared by binding an anti-immunoglobulin antibody to, forexample, a reagent capable of visualizing the employed labelingsubstance, rather than an anti-immunoglobulin antibody being employedsolely as the detection element.

In any of the aforementioned cases, in order to visualize the labelingsubstance, the detection element such as an anti-immunoglobulin antibodyis preferably bound to the detection section 23, such that the detectionelement does not migrate from the section 23 together with a liquidphase by means of capillary action. No particular limitations areimposed on the binding state of the detection element, so long as thedetection element does not migrate from the detection section 23together with a liquid phase. For example, in the case where thedetection element is an antibody which binds to a portion (other thanthe paratope) of the antibody specific to an environmental pollutant tobe detected, when a solution of the detection element (antibody) isadded dropwise to the corresponding portion of the detection section 23,a desired binding state of the detection element is established.

Finally, the absorption section 24 absorbs a liquid phase which hasmigrated from the upstream side toward the downstream side. In thepresent detection instrument B 30, the absorption section 24 is anoptional element. However, the absorption section 24 is preferablyprovided on the detection instrument for facilitating migration of thetest sample through the membrane.

As described above, in the case where the test sample contains a targetsubstance, in the present detection instrument B 30, the targetsubstance (i.e., low-molecular-weight compound) binds, in the container292, to the labeled antibody 291 which reacts specifically with thetarget substance, to thereby form a labeled complex. Subsequently, thethus-formed labeled complex comes into contact with the reaction productcontact section 21, and then migrates through the membrane 25. Thelabeled complex is not captured by the unbound labeled antibodycapturing section 22, but the complex reaches the detection section 23.Since a substance capable of visualizing the labeled complex is fixatedonto the detection section 23, the complex is concentrated at thesection 23, whereby a visually observable band of the complex isdetected.

Meanwhile, in the case where the test sample contains no targetsubstance, a labeled complex as described above is not formed, and thefree labeled antibody migrates through the membrane together with aliquid-phase. The free labeled antibody is almost completely captured bythe unbound labeled antibody capturing section 22, and thus virtually nolabeled antibody reaches the detection section 23. As a result, a bandof the labeled antibody is virtually not detected at the detectionsection 23.

Thus, when the present use method is carried out by use of the presentdetection instrument B 30 or the present detection set including theinstrument as an element, an environmental pollutant, etc. can bedetected by use of a positive index. Furthermore, as described above,there can be suppressed false-positive reaction due to the presence ofan excess amount of unbound labeled antibody, which reaction tends tooccur in the aforementioned conventional detection instrument employingimmunochromatography.

The present detection instrument B 30 is an embodiment of the presentinvention, and different embodiments of the invention may be made withinthe scope of the invention. For example, the present invention may beapplied to immunochromatography, in which a labeled antibody that is notcaptured by a line bound onto a membrane, which line can capture areaction product (labeled complex), is detected, whereby a targetsubstance is detected by use of a negative index.

EXAMPLES

The present invention will next be described in more detail by way ofExamples.

A. Example in Relation to the Present Detection Instrument A

A1. Formation of Immunogen for Preparation of Co—PCB #126 MonoclonalAntibody

A hapten targeting Co—PCB #126; i.e.,6-[(3,3,4,5-tetrachlorobiphenyl-4-yl)oxy]hexanoic acid(low-molecular-weight compound 126), was synthesized by means of aslight modification of the 6-[(3,3,4-trichlorobiphenyl-4-yl)oxy]hexanoicacid synthesis method which had previously been reported by Ya-Wen Chiu,et al. (Analytical Chemistry, 1995, 67, 3829).

Specifically, 2-chloroanisole and 3,4,5-trichloroaniline were subjectedto cadogan coupling reaction, to thereby synthesize3,3′,4′,5′-tetrachloro-4-methoxybiphenyl (yield: 12%); thethus-synthesized 3,3′,4′,5′-tetrachloro-4-methoxybiphenyl was subjectedto demethylation reaction with boron tribromide, to thereby form3,3′,4′,5′-tetrachloro-4-hydroxybiphenyl (yield: 90%); the thus-formed3,3′,4′,5′-tetrachloro-4-hydroxybiphenyl was reacted with ethyl6-bromohexanoate, to thereby form6-[(3,3′,4′,5′-tetrachloro-4-yl)oxy]hexanoate (yield: 90%); and thethus-formed [(3,3′,4′,5′-tetrachloro-4-yl)oxy]hexanoate was hydrolyzedwith an alkali, to thereby synthesize6-[(3,3′,4′,5′-tetrachloro-4-yl)oxy]hexanoic acid (yield: 95%).

The thus-synthesized hapten was bound to limulus hemocyanin (KLH)by-means of the NHS ester method employing N-hydroxysuccinimide (P.Schneider and B. D. Hammock, Journal of Agricultural and Food Chemistry,1992, 2, 85), and the resultant product was employed as an antigen forpreparation of a Co—PCB #126 monoclonal antibody.

Specifically, the above-synthesized hapten was formed into an activeester by use of 1-ethyl-3-[3-(dimethylamino)propyl)carbodiimide andN-hydroxysuccinimide, and then reacted with KLH to form an amide bondbetween the hapten and the amino group of KLH, thereby yielding ahapten-KLH conjugate.

A2. Preparation of Co—PCB #126 Monoclonal Antibody

A balb/c mouse was immunized with the Co—PCB #126 low-molecular-weightcompound-KLH conjugate which had been formed and purified through theabove-described method and with Ribi Adjuvant System (product of Corixa)at intervals of two weeks (up to eight times), and then subjected tobooster at the caudal vein. Thereafter, antibody-producing cells in thespleen and myeloma cells were subjected to cell fusion by means of acustomary method. The resultant culture supernatant containinghybridomas was subjected to screening by use of a plate on which theCo—PCB #126 low-molecular-weight compound-protein conjugate wasimmobilized, to thereby select a hybridoma which produces an antibodythat reacts specifically with Co—PCB #126.

The antibody employed in the present experiment was prepared through thefollowing procedure: the above-selected hybridoma was intraperitoneallyadministered to a mouse treated with pristane, ascites was collectedfrom the mouse by means of a customary method, and then thethus-collected ascites was subjected to purification throughanion-exchange chromatography.

A3. Preparation of Low-molecular-weight Compound-protein Conjugate to beImmobilized-onto Unbound Label Product Caputuring Section ofChromatomembrane

The low-molecular-weight compound 126 which had been synthesized abovein Al was bound to bovine serum albumin (BSA) in a manner similar tothat described above in Al, and the resultant product was purifiedthrough dialysis. The thus-obtained product was employed as alow-molecular-weight compound-protein conjugate to be immobilized ontoan unbound label product capturing section of a chromatomembrane.

A4. Preparation of Chromatomeembrane

The low-molecular-weight compound 126-BSA conjugate which had beenformed above in A3, which constitutes an unbound label product capturingsection, was applied to Hi-Flow Plus Membrane (HF90, 25 mm×30 cm,Millipore) at a position 5 mm away from the lower end thereof.Meanwhile, anti-mouse IgG rabbit antibody (Zymed), which constitutes adetection section, was applied to the membrane at a position 15 mm awayfrom the lower end thereof. The solutions of the conjugate and antibodywere applied, by use of XYZ Handling System (BioDot), to the membrane soas to form lines. After completion of application, the membrane wasallowed to stand at room temperature overnight for drying, and then wasemployed as a chromatomembrane.

A5. Preparation of Gold-colloidal-particles-labeled anti-Co—PCBMonoclonal Antibody

Gold colloidal particles (average particle size: about 40 nm,BBInternational) were bound to an anti-Co—PCB monoclonal antibodyaccording to the protocol by BBInternational. The OD520 of the resultantgold-colloid-labeled anti-Co—PCB monoclonal antibody solution wasregulated to 5 to 6, and the solution was refrigerated until employed.

A6. Preparation of Gold Colloid Pad (Label Product Reaction Section)

A glass fiber-made conjugate pad (10 mm×30 cm, product of Millipore) wasimpregnated with the above-prepared gold-colloid-labeled antibodysolution (final concentration: 16%), and then completely dried by use ofa vacuum drying machine. The resultant pad was employed as a goldcolloid pad.

A7. Preparation of Sample Pad (Test Sample Application Section)

A sample pad (20 mm×30 cm, Millipore) was impregnated with a PBSsolution containing 2% sucrose, 1% BSA, and 1% Triton X-100, and thencompletely dried by use of a vacuum drying machine. The resultant padwas employed as a sample pad.

A8. Assembly of the Present Detection Instrument A

The above-prepared sample pad, gold colloid pad, and chromatomembranewere mounted on a laminate card (Millipore) as shown in FIGS. 1 and 2.Furthermore, an absorption pad (17 mm×30 cm, product of Millipore) wasmounted on the card, and subsequently, the resultant card was cut intopieces having a width of 5 mm by use of a guillotine cutter (BioDot).Each of the pieces was employed as the-present detection instrument A.

A9. Measurement of Co—PCB #126

Co—PCB #126 was diluted with a TBS solution containing 25% DMSO so thatthe Co—PCB #126 concentration became 10 ppm, 5 ppm, 2.5 ppm, 1.25 ppm, 1ppm, or 0.1 ppm. The thus-diluted Co—PCB #126 sample (150 μL) was addeddropwise to the test sample application section of the present detectioninstrument assembled above in A8. The degree of coloring of thedetection section was evaluated through visual observation at differentpoints in time (see Table 1) after addition of the sample. The resultsare shown in Table 1. TABLE 1 Co-PCB 126 Degree of coloring of detectionsection concentration 3 minutes 5 minutes 10 minutes 20 minutes (ppm)later later later later 10 − − + ++ 5 − + ++ ++ 2.5 + + ++ ++ 1.25 + +++ ++ 1 − − + + 0.1 − − − − 0 − − − −[Evaluation criteria]++: high coloring degree,+: low coloring degree,−: no coloring

A10. Results

As is clear from Table 1, when the concentration of Co—PCB in the sampleis 1 ppm or more, the sample is-determined to be positive through visualevaluation 10 minutes after addition of the sample to the detectioninstrument.

B. Example in Relation to the Present Detection Instrument B

B1. Formation of Immunogen for Preparation of Co—PCB #118 MonoclonalAntibody

A low-molecular-weight compound targeting Co—PCB #118; i.e.,6-[(3,2′,4′,5′-tetrachlorobiphenyl-4-yl)oxy]hexanoic acid(low-molecular-weight compound 118), was synthesized by means of aslight modification of the6-[(3,3′,4′-trichlorobiphenyl-4-yl)oxy]hexanoic acid synthesis methodwhich had previously been reported by Ya-Wen Chiu, et al. (AnalyticalChemistry, 1995, 67, 3829).

The thus-synthesized low-molecular-weight compound was bound to limulushemocyanin (KLH) by means of the NHS ester method employingN-hydroxysuccinimide (P. Schneider and B. D. Hammock, Journal ofAgricultural and Food Chemistry, 1992, 2, 85), and the resultant productwas-employed as an antigen for preparation of a Co—PCB #118 monoclonalantibody.

B2. Preparation of Co—PCB #118 Monoclonal Antibody

A balb/c mouse was immunized with the Co—PCB #118 low-molecular-weightcompound-KLH conjugate which had been formed and purified through theabove-described method and with Ribi Adjuvant System (product of Corixa)at intervals of two weeks (up to eight times), and then subjected tobooster at the caudal vein. Thereafter, antibody-producing cells in thespleen and myeloma cells were subjected to cell fusion by means of acustomary method. The resultant culture supernatant containinghybridomas was subjected to screening by use of a plate on which theCo—PCB #118 low-molecular-weight compound-protein conjugate wasimmobilized, to thereby select a hybridoma which produces an antibodythat reacts specifically with Co—PCB #118.

The antibody employed in the present experiment was prepared through thefollowing procedure: the above-selected hybridoma was intraperitoneallyadministered to a mouse treated with pristane, ascites was collectedfrom the mouse by means of a customary method, and then thethus-collected ascites was subjected to purification throughanion-exchange chromatography.

B3. Preparation of Low-molecular-weight Compound-protein Conjugate to beImmobilized onto Unbound Labeled Antibody Caputuring Section ofChromatomembrane

The low-molecular-weight compound 118 which had been synthesized abovein B1 was-bound to bovine serum albumin (BSA) in a manner similar tothat described above in B1, and the resultant product was purifiedthrough dialysis. The thus-obtained product was employed as alow-molecular-weight compound-protein conjugate to be immobilized ontoan unbound labeled antibody capturing section of a chromatomembrane.

B4. Preparation of Chromatomembrane

The low-molecular-weight compound 118-BSA conjugate which had beenformed above in B3, which constitutes an unbound labeled antibodycapturing section, was applied to Hi-Flow Plus Membrane (HF90, 25 mm×30cm, Millipore) at a position 5 mm away from the lower end thereof.Meanwhile, anti-mouse IgG rabbit antibody (Zymed), which constitutes adetection section, was applied to the membrane at a position 15 mm awayfrom the lower end thereof. The solutions of the conjugate and antibodywere applied, by use of XYZ Handling System (BioDot), to the membrane soas to form lines. After completion of application, the membrane wasallowed to stand at room temperature overnight for drying, and then wasemployed as a chromatomembrane.

B5. Preparation of Gold-colloidal-particles-labeled Anti-Co—PCBMonoclonal Antibody

Gold colloidal particles (average particle size: about 40 nm,BBInternational) were bound to the anti-Co—PCB monoclonal antibodyprepared above in B2 according to the protocol by BBInternational. TheOD520 of the resultant gold-colloid-labeled anti-Co—PCB monoclonalantibody solution was regulated to 5 to 6, and the solution wasrefrigerated until employed.

B6. Assembly of Conjugate-pad-mounted Detection Instrument

A glass fiber-made conjugate pad (10 mm×30 cm, product of Millipore) wasimpregnated with the above-prepared gold-colloid-labeled antibodysolution (final concentration: 16%), and then completely dried by use ofa vacuum drying machine. The resultant pad was employed as a goldcolloid pad. Separately, a cotton pad (20 mm×30 cm, product ofMillipore) was impregnated with a PBS solution containing 2% sucrose, 1%BSA, and 1% Triton X-100, and then completely dried by use of a vacuumdrying machine. The resultant pad was employed as a sample pad. Thesepads and the chromatomembrane prepared above in B4 were mounted on alaminate card (product of Millipore). Furthermore, an absorption pad (17mm×30 cm, product of Millipore) was mounted on the card, andsubsequently, the resultant card was cut into pieces having a width of 5mm by use of a guillotine cutter (product of Biobot). Each of the pieceswas employed as an immunochromatography instrument.

B7. Preparation of Labeled Antibody and Detection Instrument Employed inthe Present use Method (the Present Detection Set)

A mixture (100 μl) of the gold-colloid-labeled antibody solutionprepared above in B5 (final concentration: 1%) and a sucrose solution(final concentration: 3%) was-added to a 1.5-ml plastic-made Eppendorftube, and then completely dried by use of a vacuum drying machine. Theresultant product was employed as a dried, labeled antibody. A glassfiber filter (Schleicher & Schuell), serving as a reaction productcontact section, and the chromatomembrane prepared above in B∝weremounted on a laminate card (product of Millipore). Furthermore, anabsorption pad (17 mm x 30 cm, product of Millipore) was mounted on thecard, and subsequently, the resultant card was cut into pieces having awidth of 5 mm by use of a guillotine cutter (product of BioDot). Each ofthe pieces was employed as an immunochromatography instrument.

B8. Detection of Co—PCB #118 by Use of Conjugate-pad-mounted DetectionInstrument A

Co—PCB #118 was diluted with a TBS solution containing 20% DMSO so thatthe Co—PCB #118 concentration became 200 ppm, 20 ppm, 2 ppm, 0.2 ppm, or0.02 ppm. The thus-diluted Co—PCB #118 sample (150 μL) was addeddropwise to the test sample application section of the detectioninstrument. The degree of coloring of the detection section wasevaluated through visual observation at different points in time (seeTable 2) after addition of the sample. The results are shown in Table 2.TABLE 2 Co-PCB 118 Degree of coloring of detection section concentration3 minutes 5 minutes 10 minutes 20 minutes (ppm) later later later later200 − − + ++ 20 − − + ++ 2 − − + + 0.2 − − − − 0.02 − − − − 0 − − − −[Evaluation criteria]++: high coloring degree,+: low coloring degree,−: no coloring

B9. Detection of Co—PCB #118 by Use of the Present Detection Instrument

Co—PCB #118 was diluted with a TBS solution containing 20% DMSO so thatthe Co—PCB #118 concentration became 200 ppm, 20 ppm, 2 ppm, 0.2 ppm, or0.02 ppm. The thus-diluted Co—PCB #118 solution (150 μL) was completelymixed with the dried, labeled antibody obtained above in B7, and theresultant mixture was added dropwise to the reaction product contactsection of the present detection instrument prepared above in B7. Thedegree of coloring of the detection section was evaluated through visualobservation at different points in time (see Table 3) after addition ofthe mixture. The results are shown in Table 3. TABLE 3 Co-PCB 118 Degreeof coloring of detection section concentration 3 minutes 5 minutes 10minutes 20 minutes (ppm) later later later later 200 − + ++ ++ 20 − + ++++ 2 − + ++ + 0.2 − − + + 0.02 − − − − 0 − − − −[Evaluation criteria]++: high coloring degree,+: low coloring degree,−: no coloring

B10. Results

In the case where the conjugate-pad-mounted detection instrument A wasemployed, Co—PCB #118 of 2 ppm or more was determined to be positivethrough visual evaluation 20 minutes after addition of the Co—PCB #118sample to the detection instrument A. In contrast, in the case where thepresent use method was performed by use of the present detectioninstrument B, Co—PCB #118 of 0.2 ppm or more was determined to bepositive; i.e., the detection sensitivity of the instrument B was foundto be higher by a factor of 10 or more than that of theconjugate-pad-mounted detection instrument A, which is of a conventionaltype.

B11. Semi-quantification of Co—PCB #118

In both the cases of the present detection instrument B and theconventional-type conjugate-pad-mounted detection instrument A, Co—PCB#118, which is a target substance, was semi-quantified; i.e., the levelof the target substance present in the test sample was determined, byuse, as indexes, of the degree of coloring of the detection section andthe degree of coloring of the unbound labeled antibody capturingsection. Specifically, in the case of the conjugate-pad-mounteddetection instrument A, data on the degree of coloring of the unboundlabeled antibody capturing section were added to the data on the degreeof coloring of the detection section shown in Table 2. The results areshown in Table 4. TABLE 4 Degree of coloring of detection section(right) Degree of coloring of unbound labeled Co-PCB 118 antibodycapturing section (left) concentration 3 minutes 5 mintues 10 minutes 20minutes (ppm) later later later later 200 − − − − − + − ++ 20 − − − −− + − ++ 2 − − + − + + + + 0.2 − − + − + − ++ − 0.02 − − + − ++ − ++ − 0− − + − ++ − ++ −[Evaluation criteria]++: high coloring degree,+: low coloring degree,−: no coloring

As is clear from Table 4, in the case of the conjugate-pad-mounteddetection instrument A, 1) when low degree of coloring or no coloring ofthe unbound labeled antibody capturing section is observed, and whenhigh degree of coloring of the detection section is observed, the Co—PCB118 concentration is 20 ppm or more; 2) when coloring of the unboundlabeled antibody capturing section and coloring of the detection sectionare observed,.the Co—PCB 118 concentration is 2 to 20 ppm; and 3) whenhigh degree of coloring of the unbound labeled antibody capturingsection and no coloring of the detection section are observed, theCo—PCB 118 concentration is ppm or less.

Meanwhile, in the case of the-present detection instrument B, data onthe degree of coloring of the unbound labeled antibody capturing sectionwere added to the data on the degree of coloring of the detectionsection shown in Table 3. The results are shown in Table 5. TABLE 5Degree of coloring of detection section (right) Degree of coloring ofunbound labeled Co-PCB 118 antibody capturing section (left)concentration 3 minutes 5 minutes 10 minutes 20 minutes (ppm) laterlater later later 200 − − − + − ++ − ++ 20 − − − + − ++ − ++ 2 − − + + +++ + + 0.2 − − + − + + ++ − 0.02 − − + − ++ − ++ − 0 − − + − ++ − ++ −[Evaluation criteria]++: high coloring degree,+: low coloring degree,−: no coloring

As is clear from Table 5, 1) when very low degree of coloring or nocoloring of the unbound labeled antibody capturing section is observed,and when high degree of coloring of the detection section is observed,the Co—PCB 118 concentration is 20 ppm or more; 2) when low degree ofcoloring of the unbound labeled antibody capturing section and highdegree of coloring of the detection section are observed, the Co—PCB 118concentration is 2 to 20 ppm; 3) when high degree of coloring of theunbound labeled antibody capturing section and low degree of coloring ofthe detection section are observed, the Co—PCB 118 concentration is 0.2to 2 ppm; and 4) when high degree of coloring of the unbound labeledantibody capturing section and no coloring of the detection section areobserved, the Co—PCB 118 concentration is 0.2 ppm or less.

Industrial Applicability

The present invention provides means for conveniently and sensitivelydetecting a low-molecular-weight substance such as an environmentalpollutant (e.g., a dioxin), which is a target substance contained in atest sample, which means enables suppression of, for example,false-positive reaction.

1. A low-molecular-weight substance detection instrument employingimmunochromatography, comprising a test sample application section withwhich a test sample is brought into contact, wherein a target substancecontained in the test sample brought into contact with the test sampleapplication section is detected by use, as an index, of a labelingsubstance employed in a label product containing, as a portion thereof,an antibody capable of binding to the target substance contained in thetest sample.
 2. A low-molecular-weight substance detection instrumentaccording to claim 1, which comprises 1) a test sample applicationsection with which a test sample is brought into contact; 2) a labelproduct reaction section containing a label product containing, as aportion thereof, an antibody capable of binding to a target substancecontained in the test sample, the label product being not bound to thereaction section; 3) an unbound label product capturing sectioncontaining-an element capable of capturing the label product which isnot bound to the target substance, the element being bound to thecapturing section; and 4) a detection section containing a detectionelement which, when coming into contact with the target substance boundto the label product, causes a visually observable change.
 3. Alow-molecular-weight substance detection instrument according to claim1, wherein a test sample is reacted with a labeled antibody containing,as a portion thereof, an antibody capable of binding to a targetsubstance contained in the test sample, and the resultant reactionproduct is employed for detecting the target substance contained in thetest sample.
 4. A low-molecular-weight substance detection instrumentaccording to claim 3, which comprises the following 1) and 2): 1) anunbound labeled antibody capturing section containing an element capableof capturing the labeled antibody which is not bound to the targetsubstance, the element being bound to the capturing section; and 2) adetection section containing a detection element which, when coming intocontact with the target substance bound to the labeled antibody, causesa visually observable change.
 5. A low-molecular-weight substancedetection instrument according to claim 2, wherein the detection elementcontained in the detection section is metallic colloidal particles orlatex particles.
 6. A low-molecular-weight substance detectioninstrument according to claim 2, wherein the detection element containedin the detection section is bound to the detection section.
 7. Alow-molecular-weight substance detection instrument according to claim2, wherein the element capable of capturing the label product which isnot bound to the target substance, which is contained in the unboundlabel-product capturing section, is the target substance or a substancesimilar to the target substance.
 8. A low-molecular-weightsubstance-detection instrument according to claim 2, wherein each of theunbound label product capturing section and the detection sectioncomprises, as a base, a carrier fixated onto a porous membrane forchromatography.
 9. A low-molecular-weight substance detection instrumentaccording to claim 1, wherein the target substance is a dioxin and/or aPCB.
 10. A method of using a low-molecular-weight substance detectioninstrument as recited in claim 3, which comprises bringing, into contactwith the test sample application section, a reaction product formed froma test sample and a labeled antibody containing, as a portion thereof,an antibody capable of binding to a target substance contained in thetest sample; and detecting a complex of the labeled antibody and thetarget substance, the complex being contained in the reaction product,and/or the labeled antibody which is not bound to the target substance,to thereby detect the target substance contained in the-test sample. 11.A low-molecular-weight substance detection set comprising alow-molecular-weight substance detection instrument as recited in claim3, and a labeled antibody containing, as a portion thereof, an antibodycapable of binding to a target substance contained in a test sample. 12.A low-molecular-weight substance detection set according to claim 11,wherein the labeled antibody containing, as a portion thereof, anantibody capable of binding to a target substance contained in a testsample is maintained in a dry condition.
 13. A low-molecular-weightsubstance detection instrument according to claim 4, wherein thedetection element contained in the detection section is metalliccolloidal particles or latex particles.
 14. A low-molecular-weightsubstance detection instrument according to claim 4, wherein thedetection element contained in the detection section is bound to thedetection section.
 15. A low-molecular-weight substance detectioninstrument according to claim 4, wherein the element capable ofcapturing the labeled antibody which is not bound to the targetsubstance, which is contained in the unbound labeled antibody capturingsection, is the target substance or a substance similar to the targetsubstance.
 16. A low-molecular-weight substance detection instrumentaccording to claim 4, wherein each of the unbound labeled antibodycapturing section and the detection section comprises, as a base, acarrier fixated onto a porous membrane for chromatography.